Investigator-sponsored study of imetelstat in combination with venetoclax or azacitidine in relapsed/refractory acute-myeloid-leukaemia patients
Latest Information Update: 18 Mar 2022
At a glance
- Drugs Azacitidine (Primary) ; Imetelstat (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TELOMERE
- 10 Mar 2022 According to a Geron Corporation media release, the company expect to initiate this study in 2H 2022
- 22 Nov 2021 New trial record
- 09 Nov 2021 According to a Geron Corporation media release, the company expect to initiate this study in the first half of 2022.